BIOVIE INC.
For the period ended Jun 30, 2025. Filed Aug 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Aug 15, 2025
BIVI$1.19-5.6%Stored close · as of Nov 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
Checking your notes…
| Year Ended | Year Ended | |
|---|---|---|
| June 30, 2025 | June 30, 2024 | |
| OPERATING EXPENSES: | ||
| Amortization of intangible assets | $229,377 | $229,377 |
| Research and development expenses | 9,266,734 | 23,100,394 |
| Selling, general and administrative expenses | 8,570,089 | 8,849,814 |
| TOTAL OPERATING EXPENSES | 18,066,200 | 32,179,585 |
| LOSS FROM OPERATIONS | (18,066,200) | (32,179,585) |
| OTHER EXPENSE (INCOME): | ||
| Change in fair value of derivative liabilities | (3,771) | (1,816,271) |
| Interest expense | 332,720 | 2,893,922 |
| Interest income | (853,029) | (1,136,703) |
| TOTAL OTHER INCOME , NET | (524,080) | (59,052) |
| NET LOSS | $(17,542,120) | $(32,120,533) |
| Deemed dividend related to ratchet adjustment to warrants | 369,465 | 886,423 |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | $(17,911,585) | $(33,006,956) |
| NET LOSS PER COMMON SHARE | ||
| - Basic | $(12.12) | $(73.05) |
| - Diluted | $(12.12) | $(73.05) |
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING | ||
| - Basic | 1,477,372 | 451,853 |
| - Diluted | 1,477,372 | 451,853 |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | $(17,911,585) | $(33,006,956) |
| Other comprehensive loss | ||
| Reclassification of unrealized gains on available-for-sale investments upon settlement | - | (176,591) |
| Total other comprehensive loss | - | (176,591) |
| Comprehensive loss | $(17,911,585) | $(33,183,547) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.